There was only a minority of newer P2Y12 inhibitors used as APT. There was an associated reduction in hospitalizations in the 2 rivaroxaban arms, compared with VKA.287 The RE-DUAL PCI (A Prospective, Randomized, Phase 3b Study Comparing the Safety and Ef cacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting) randomized 2,725 patients with AF who had undergone PCI to triple therapy with warfarin plus a P2Y12 inhibitor (clopidogrel or ticagrelor) and aspirin (for 1-3 months) (triple-therapy group) or dual therapy with dabigatran (110 mg or 150 mg twice daily) plus a P2Y12 inhibitor (clopidogrel or ticagrelor) and no aspirin (110-mg and 150-mg dual-therapy groups). Outside the United States, elderly patients ($ 80 years of age; $ 70 years of age in Japan) were randomly assigned to the 110-mg dual-therapy group or the triple-therapy group. The incidence of the primary end point (major or clinically relevant nonmajor bleeding) was 15.4% in the 110-mg dual-therapy group compared with 26.9% in the triple-therapy group (HR, 0.52; 95% CI, 0.42 to 0.63; P < .001 for noninferiority; P < .001 for superiority) and 20.2% in the 150-mg dual-therapy group compared with 25.7% in the corresponding triple-therapy group, which did not include elderly patients outside the United States noninferiority). The incidence of the composite ef cacy end point of thromboembolic events (MI, stroke, or systemic embolism), death, or unplanned revascularization was 13.7% in the 2 dual-therapy groups combined compared with 13.4% in the triple- therapy group (HR, 1.04; 95% CI, 0.84-1.29; P .005 for noninferiority). 